- Oviva, the leading digital provider of Type 2 diabetes treatment in Europe, has raised $21m in Series B funding.
- MTIP led the round, joined by Earlybird as new investors.
- Existing investors AlbionVC, F-Prime Capital, Eight Roads Ventures and Partech all participated.
The new capital will be used to further develop Oviva’s technology and expand in Europe to serve the millions of patients not accessing treatment today. It brings the total amount raised by Oviva to date to $34m.
Oviva offers an evidence-based digital solution to stop the progression of and reverse Type 2 diabetes and obesity-related conditions. Patients receive tailored nutrition advice and personalised coaching via their phone.
Oviva’s technology-supported treatment has consistently demonstrated higher patient uptake, retention and outcomes at lower costs compared to face-to-face therapy. They treated 90,000 patients to-date across the UK, Germany, France, Switzerland and the UAE, consistently doubling each year for the last 3 years.
